Seeking Alpha

Cadence Pharmaceuticals slips on USPTO rejection of certain claims on Ofirmev

  • Cadence Pharmaceuticals (CADX -4.6%) slips after the USPTO issued preliminary decision yesterday rejecting certain claims for one of two licensed patents underlying its Ofirmev injection, now part of a legal fight with Exela Pharma.
  • In response, CADX notes that it's very common for the USPTO to reject some or all of the claims of a patent in an initial office action, and this is not a final decision, but just one step in the reexamination process, which can take many years to complete.
  • The company doesn't expect the decision to have an adverse impact on the pending litigation against Exela.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|